Search results
Results From The WOW.Com Content Network
However, the rising dividend yield seems to be just a byproduct of the market selling Pfizer stock off for its declining sales. Management even raised guidance in Q1. Management even raised ...
The first ultra-high-yield dividend stock that makes for a no-brainer buy in the upcoming year is pharmaceutical juggernaut Pfizer (NYSE: PFE). Though Pfizer has been weighed down by shrinking ...
A high-yield dividend stock with long-term potential Pfizer's current 5.73% dividend yield stands well above the S&P 500 average of 1.35%. The company's payout ratio of 443% appears unsustainable ...
The S&P 500 Dividend Aristocrats is a stock market index composed of the companies in the S&P 500 index that have increased their dividends in each of the past 25 consecutive years. It was launched in May 2005.
An ideal stock for dividend and growth investors. David Jagielski (AbbVie): Drugmaker AbbVie is a solid all-around dividend stock, suitable for any type of investor. Its 3.2% dividend yield is ...
To be taxed at the qualified dividend rate, the dividend must: be paid after December 31, 2002; be paid by a U.S. corporation, by a corporation incorporated in a U.S. possession, by a foreign corporation located in a country that is eligible for benefits under a U.S. tax treaty that meets certain criteria, or on a foreign corporation’s stock that can be readily traded on an established U.S ...
On November 23, 2015, Pfizer and Allergan announced a planned $160 billion merger, in the largest pharmaceutical deal ever and the third largest corporate merger in history. The proposed transaction contemplated that the merged company maintain Allergan's Republic of Ireland domicile, resulting in the new company being subject to corporation ...
With a market capitalization of more than $143 billion today, Pfizer (NYSE: PFE) stock won't make anyone into a millionaire unless they're willing to commit a large amount of capital and then hold ...